IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

17 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

11 7 2024 18:40:40 提供 Nasdaq GlobeNewswire

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

03 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

25 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep successfully completes institutional placement and institutional component of entitlement offer

05 6 2024 06:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

02 6 2024 20:38:39 提供 Nasdaq GlobeNewswire

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

15 5 2024 08:00:01 提供 Nasdaq GlobeNewswire

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

02 5 2024 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q3 FY24

29 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

24 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

18 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

17 4 2024 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces First Clinical Data from 90mg Dosing of Efti

05 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q2 FY24

30 1 2024 08:00:00 提供 Nasdaq GlobeNewswire

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

04 1 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

21 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

07 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

22 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

09 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

06 11 2023 08:00:01 提供 Nasdaq GlobeNewswire